JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265712

Human ACOX3 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ACOX3 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 5 and 5 bp deletion in exon 5. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human ACOX3 knockout HeLa cell line (AB265712)
  • Sanger seq

Unknown

Sanger Sequencing - Human ACOX3 knockout HeLa cell line (AB265712)

Allele-2 : 5 bp deletion in exon 5.

Sanger Sequencing - Human ACOX3 knockout HeLa cell line (AB265712)
  • Sanger seq

Unknown

Sanger Sequencing - Human ACOX3 knockout HeLa cell line (AB265712)

Allele-1 : 16 bp deletion in exon 5.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 5 and 5 bp deletion in exon 5

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265712-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265712-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265712 Human ACOX3 knockout HeLa cell line", "number":"AB265712-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265712-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265712-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265712 Human ACOX3 knockout HeLa cell line", "number":"AB265712-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265712-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265712 Human ACOX3 knockout HeLa cell line", "number":"AB265712-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265712-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265712 Human ACOX3 knockout HeLa cell line", "number":"AB265712-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ACOX3
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ACOX3 also known as acyl-CoA oxidase 3 or PRACOX3 is an enzyme that functions in the peroxisomal beta-oxidation of branched-chain fatty acids. It specifically catalyzes the first oxidation step introducing a double bond between alpha and beta carbon of Acyl-CoA esters. ACOX3 has a molecular mass of approximately 75 kDa. Expression of ACOX3 primarily occurs in liver and kidney tissues where it plays a significant role in lipid metabolism.
Biological function summary

ACOX3 contributes to the breakdown of pristanic acid a branched-chain fatty acid derived from phytanic acid. It functions as part of a peroxisomal enzyme system that efficiently oxidizes fatty acids that contain branches on their carbon chains which mitochondria can't oxidize. ACOX3 works alongside other enzymes like ACOX1 and ACOX2 which oxidize different substrates ensuring a specialized fatty acid metabolism in the cell.

Pathways

ACOX3 plays a critical role in the peroxisomal fatty acid beta-oxidation pathway also contributing to the catabolism of very-long-chain fatty acids. This pathway complements the mitochondrial beta-oxidation providing a synergistic approach for complete fatty acid degradation. ACOX3 works closely related to proteins like peroxisomal bifunctional enzyme and thiolase completing the sequential steps necessary for beta-oxidation and energy production from fatty acids.

Mutations or dysfunctions in ACOX3 can lead to disruptions in fatty acid metabolism particularly affecting the metabolism of branched-chain fatty acids and potentially contributing to conditions such as Refsum disease or Zellweger syndrome. These disorders often exhibit accumulation of toxic metabolites causing harmful effects in tissues. They link ACOX3 dysfunction to broader peroxisomal biogenesis issues that involve other enzymes such as the PEX proteins which are vital for normal peroxisomal function and maintenance.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com